Sanofi's third quarter earnings disappointed the market, with revenues coming in below consensus expectations – still, sales of its recently approved eczema drug, Dupixent, were much stronger than expected.
The company saw a weak growth rate for its leading multiple sclerosis drugs Aubagio (teriflunomide) and Lemtrada (alemtuzumab) in the quarter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?